Evonetix Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 79
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $29.4M
Latest Deal Amount
  • Investors
  • 11

Evonetix General Information

Description

Developer of a desktop platform designed to synthesize DNA at higher accuracy and scale. The company's platform places DNA synthesis in the hands of every researcher and changes how DNA is accessed, made, and used for gene synthesis, enabling scientists to use synthetic biology on a scale not currently possible.

Contact Information

Formerly Known As
Tayvin 486 Limited
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
  • 9a Coldham's Business Park
  • Norman Way
  • Cambridge CB1 3LH
  • England, United Kingdom
+44 01223 000000

Evonetix Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Evonetix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 02-Mar-2020 $29.4M 000.00 000.00 Completed Generating Revenue
4. Grant 02-Jul-2018 00.000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 30-Jan-2018 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 20-Jul-2016 Completed Generating Revenue
1. Angel (individual) 01-Jan-2015 Completed Startup
To view Evonetix’s complete valuation and funding history, request access »

Evonetix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B2 Preferred 000,000 00.000000 000 000 00 000 0.000
B1 Preferred 000,000 00.000000 000 000 00 000 00.000
B Preferred 000,000 00.000000 000 000 00 000 00.000
A Preferred 000,000 00.000000 000.00 000.00 00 000.00 0.000
A Preferred 859,433 $0.012961 $12.83 $12.83 1x $12.83 24.75%
Pref A Ordinary 500,000 $0.012961 $5.18 $5.18 1x $5.18 14.4%
To view Evonetix’s complete cap table history, request access »

Evonetix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a desktop platform designed to synthesize DNA at higher accuracy and scale. The company's platform places D
Other Healthcare Technology Systems
Cambridge, United Kingdom
79 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

0000000

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Menlo Park, CA
000 As of 0000
00000
000000000 00000

00000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000000000 000000000
Redwood City, CA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evonetix Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pacific Biosciences Formerly VC-backed Menlo Park, CA 000 00000 000000000 00000
00000000 Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
000000 Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
000000 Formerly VC-backed Providence, RI 00 0000 000000000 - 0000
000000000 Formerly VC-backed San Francisco, CA 0 000000&0
You’re viewing 5 of 35 competitors. Get the full list »

Evonetix Patents

Evonetix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201812169-D0 Accessing data storage provided using double-stranded nucleic acid molecules Granted 26-Jul-2018 000000000
US-20210280274-A1 Accessing data storage provided using double-stranded nucleic acid molecules Pending 26-Jul-2018 000000000
GB-2576304-B Accessing data storage provided using double-stranded nucleic acid molecules Active 26-Jul-2018 000000000 0
GB-2576304-A Accessing data storage provided using double-stranded nucleic acid molecules Granted 26-Jul-2018 000000000 0
EP-3827435-A1 Accessing data storage provided using double-stranded nucleic acid molecules Pending 26-Jul-2018 G16B50/00

Evonetix Executive Team (5)

Name Title Board Seat Contact Info
Matthew Hayes Ph.D Co-Founder, Chief Technology Officer & Interim Chief Executive Officer
Joseph Brennan Ph.D Co-Founder & Chief Scientific Officer
Malcolm Gates Vice President Of Finance
You’re viewing 3 of 5 executive team members. Get the full list »

Evonetix Board Members (8)

Name Representing Role Since
Hermann Hauser Ph.D Self Board Observer 000 0000
James Tananbaum MD Self Board Member 000 0000
Jason Pontin DCVC Board Member 000 0000
Nicholas McCooke Self Board Member 000 0000
Paul Beastall Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Evonetix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evonetix Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Cambridge Consultants Corporation Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Draper Esprit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »